

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
B cell lymphoma	ATP-binding cassette sub-family A member 3 (ABCA3)	<p>Cell culture studies suggest inhibiting ABCA3 could increase the efficacy of anti-CD20 therapies for B cell lymphoma. In cultured B cell lymphoma cells, small hairpin RNA knockdown of ABCA3 increased sensitivity to Rituxan rituximab compared with that seen using control shRNA. Next steps include studying clinical samples.</p> <p>Rituxan, a mAb against CD20 from Biogen Idec Inc. and the Genentech Inc. subsidiary of Roche, is marketed for a variety of autoimmune diseases and hematological cancers.</p> <p>Arzerra ofatumumab, a mAb against CD20 from Genmab A/S and GlaxoSmithKline plc, is marketed for chronic lymphocytic leukemia (CLL).</p> <p>SciBX 4(36); doi:10.1038/scibx.2011.1010 Published online Sept. 15, 2011</p>	Patent application filed; licensing status undisclosed	<p>Aung, T. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Aug. 25, 2011; doi:10.1073/pnas.1102855108</p> <p>Contact: Gerald G. Wulf, University of Goettingen, Goettingen, Germany e-mail: gwulf@med.uni-goettingen.de</p>